21 March 2012, Clinical and Vaccine Immunology, 780-786
Hepatitis C virus-multi-specific T-cell responses without viremia or seroconversion among egyptian healthcare workers at high risk of infection
S. Abdelwahab, Z. Zakaria, M. Sobhy, E. Rewisha, M.A. Mahmoud, M.A. Amer, M. Del Sorbo, S. Capone, A. Nicosia, A. Folgori, M. Hashem, S.S. El-Kamary
http://www.ncbi.nlm.nih.gov/pubmed?term=Hepatitis%20C%20Virus-Multi-Specific%20T-Cell%20Responses%20without%20Viremia%20or%20Seroconversion%20among%20Egyptian%20Healthcare%20Workers%20at%20High%20Risk%20of%20Infection
February 2012, Hepatology, 55(2):364-72
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo
P. Meuleman, M.T. Catanese, L. Verhoye, I. Desombere, A. Farhoudi, C.T. Jones, T. Sheahan, K. Grzyb, R. Cortese, C.M.Rice, G. Leroux-Roels, A. Nicosia
http://www.ncbi.nlm.nih.gov/pubmed?term=A%20human%20monoclonal%20antibody%20targeting%20scavenger%20receptor%20class%20B%20type%20I%20precludes%20hepatitis%20C%20virus%20infection%20and%20viral%20spread%20in%20vitro%20and%20in%20vivo
February 2012, Transactions of The Royal Society of Tropical Medicine and Hygiene, 106: 98-103
Risk factor for Hepatitis C Virus infection among egyptian healthcare workers in a national liver diseases referral centre
S. Abdelwahab, E. Rewisha, M. Hashem, M. Sobhy, I. Galal, W.R. Allam, N. Mikhail, G. Galal, M. El-Tabbakh, S.S. El-Kamary, I. Waked, G.T. Strickland
http://www.ncbi.nlm.nih.gov/pubmed?term=Risk%20factor%20for%20Hepatitis%20C%20Virus%20infection%20among%20egyptian%20healthcare%20workers%20in%20a%20national%20liver%20diseases%20referral%20centre
4 January 2012, Science Translational Medicine 4, 115ra1
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
E. Barnes, A. Folgori, S. Capone, L. Swadling, S. Aston, A. Kurioka, J. Meyer, R. Huddart, K. Smith, R. Townsend, A. Brown, R. Antrobus, V. Ammendola, M. Naddeo, G. O'Hara, C. Willberg, A. Harrison, F. Grazioli, M.L. Esposito, L. Siani, C. Traboni, Y. Oo, D. Adams, A. Hill, S. Colloca, A. Nicosia, R. Cortese, P. Klenerman
http://stm.sciencemag.org/content/4/115/115ra1
January 2012, Science Translational Medicine 4, 115ra2
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species
S. Colloca, E. Barnes, A. Folgori, V. Ammendola, S. Capone, A. Cirillo, L. Siani, M. Naddeo, F. Grazioli, M.L. Esposito, M. Ambrosio, A. Sparacino, M. Bartiromo, A. Meola, K. Smith, A. Kurioka, G.A. O'Hara, K.J. Ewer, N. Anagnostou, C. Bliss, A. Hill, C. Traboni, P. Klenerman, R. Cortese, A. Nicosia
http://stm.sciencemag.org/content/4/115/115ra2.abstract?sid=eade8c3d-b573-4041-8354-ef0be31338c2
May 2011, Nature Reviews, Gastroenterology & Hepatology, 8(5): 257-264
A new standard of care for the treatment of chronic HCV infection
W.P. Hofmann, S. Zeuzem
http://www.ncbi.nlm.nih.gov/pubmed/21468124
March 2011, Hepatology, 53(3):755-62
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against Hepatitis C virus
P. Meuleman, J. Bukh, L. Verhoye, A. Farhoudi, T. Vanwollehem, R.Y. Wang, I. Desombere, H. Alter, R. Purcell, G. Leroux-Roels
http://www.ncbi.nlm.nih.gov/pubmed?term=In%20vivo%20evaluation%20of%20the%20cross-genotype%20neutralizing%20activity%20of%20polyclonal%20antibodies%20against%20Hepatitis%20C%20virus
May 2010, The Journal of Infectious Diseases, 201(9): 1381-9
Challenge pools of Hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models
J. Bukh, P. Meuleman, R. Tellier, R.E. Engle, S.M. Feinstone, G. Eder, W.C. Satterfield, S. Govindarajan, K. Krawczynski, R.H. Miller, G. Leroux-Roels, R.H. Purcell
http://www.ncbi.nlm.nih.gov/pubmed?term=Challenge%20pools%20of%20Hepatitis%20C%20virus%20genotype%201-6%20prototype%20strains%3A%20replication%20fitness%20and%20pathogenicity%20in%20chimpanzees%20and%20human%20liver-chimeric%20mouse%20models
September 2009, Viruses, 1(2): 222-240
HCV Animal Models: A Journey of more than 30 Years
P. Meuleman, G. Leroux-Roels
http://www.ncbi.nlm.nih.gov/pubmed?term=HCV%20Animal%20Models%3A%20A%20Journey%20of%20more%20than%2030%20Years
June 2008, Lancet Infect Dis, 8(6): 379–86
Hepatitis C vaccine: supply and demand
G. Thomas Strickland, S.S. El-Kamary, P. Klenerman, A. Nicosia
http://www.ncbi.nlm.nih.gov/pubmed/18501853
2007, Acta Biochim Pol, 54(4): 703-15
Hepatitis C new developments in the studies of the viral life cycle
M. Rychłowska, K. Bienkowska-Szewczyk
http://www.ncbi.nlm.nih.gov/pubmed/17957276
2012, in press, Journal of Hepatology
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice
K. Lacek, K. Vercauteren, K. Grzyb, M. Naddeo, L. Verhoye, M.P. Slowikowski, S. Fafi-Kremer, A.H. Patel, T.F. Baumert, A. Folgori, G. Leroux-Roels, R. Cortese, P. Meuleman, A. Nicosia
ORAL PRESENTATIONS
8-12 September 2011, 18th International Symposium on Hepatitis C Virus and Related Viruses, Seattle, USA
Characterisation and imunogenicity of adenovector-expressed HCV glycoproteins depleted of specific glycans
A. Chmielewska, M. Naddeo, V. Ammendola, S. Colloca, A. Nicosia, F. Helle, J. Dubuisson, K. Bienkowska-Szewczyk, A. Folgori
8-12 September 2011, 18th International Symposium on Hepatitis C and Related Viruses, Seattle, USA
Enhancing T cell response and cross-neutralizing antibodies against HCV envelope by combining Adenovirus and protein
A. Chmielewska, M. Naddeo, V. Ammendola, K. Hu, L. Verhoye, M. Rychlowska, R. Rappuoli, S. Colloca, A. Nicosia, R. Cortese, G. Leroux-Roels, P. Meuleman, K. Bienkowska-Szewczyk, P. Balfe, J.A. McKeating, A. Folgori
8-12 September 2011, 18th International Symposium on HCV and related viruses, Seattle, USA
Simian adenoviral and MVA vectors combined in a heterologous prime boost strategy - A higly immunogenic novel vaccine against HCV
E. Barnes, A. Folgori, S. Capone, J. Meyer, K.E. Smith, R. Huddart, A.C. Brown, A. Kurioka, G.L.A. Harrison, C. Kelly, M. Naddeo, V. Ammendola, M. Del Sorbo, S. Colloca, L. Siani, C. Traboni, R. Cortese, A. Nicosia, P. Klenerman
30 March – 3 April 2011, The International Liver Congress 2011 – EASL, Berlin, Germany
Human monoclonal antibodies targeting SR-BI prevent HCV entry and viral spread in vivo
P. Meuleman, M.T. Catanese, L. Verhoye, I. Desombere, C.T. Jones, K. Grzyb, R. Cortese, C.M. Rice, G. Leroux-Roels, A. Nicosia
30 March – 3 April 2011, The International Liver Congress 2011 – EASL, Berlin, Germany
A therapeutic vaccine for HCV based on novel, rare, adenoviral vectors (#750)
C. Kelly, A. Folgori, S. Capone, J. Halliday, E. Stafford, D. O'Donnell, K. Gantlett, J. Collier, A.C. Brown, R. Huddart, I. Humphreys, A. Kurioka, R. Townsend, L. Swadling, V. Ammendola, S. Colloca, M. Naddeo, L. Siani, C. Traboni, H. Jones, Y. Oo, D. Adams, D. Mutimer, R. Cortese, A. Nicosia, P. Klenerman, E. Barnes
30 March – 3 April 2011, The International Liver Congress 2011 - EASL, Berlin, Germany
Phase I trial of a higly immunogenic and durable T cell vaccine for Hepatitis C virus based on novel, rare, adenoviral vectors (#1140)
E. Barnes, A. Folgori, S. Capone, S. Aston, J. Meyer, K. Gantlett, K.E. Smith, R. Huddart, A.C. Brown, A. Kurioka, I. Humphreys, G.L.A. Harrison, C. Kelly, V. Ammendola, S. Colloca, M. Naddeo, L. Siani, C. Traboni, R. Cortese, A. Nicosia, P. Klenerman
27-28 January 2011, 11ème Réunion du Réseau National Hépatites de l ’ANRS, UIC Patrimoine, Paris, France. Invited by the organizing committee
Prevention of HCV infection by targeting cellular receptors
P. Meuleman
3-8 October 2010, 12th International meeting of the Institute of Human Virology, Reggio Calabria, Italy.
Hepatitis C Virus-specific immune response among Egyptian healthcare workers at high risk of infection without viremia or seroconversion (#195)
S. Abdelwahab, E. Rewisha, M. Sobhy, I. Galal, Z.A. Zakaria, M.A. Mahmoud, S. Capone, A. Folgori, M. Hashem, S.S. El-Kamary, G.T. Strickland, R. Cortese, A. Nicosia
10-14 September 2010, 17th International Symposium on Hepatitis C and Related Viruses, Yokohama, Japan.
Prevention of Hepatitis C virus infection and suppression of viral spread by targeting SR-BI
P. Meuleman, M.T. Catanese, L. Verhoye, I. Desombere, C.T. Jones, K. Grzyb, R. Cortese, C.M. Rice, G. Leroux-Roels, A. Nicosia
10-14 September 2010, 17th International Symposium on Hepatitis C Virus and Related Viruses, Yokohama, Japan
Construction and characterization of a panel of FLAG-tagged E2 glycoproteins from hepatitis C virus
V.B. Krapchev, A. Śmieszalska, K. Solarz, A. Owsianka, A.H. Patel, K. Bienkowska-Szewczyk
19 August 2010, ImVacS The Immunotherapeutics Vaccine Summit, Cambridge, MA, USA. Invited speaker
Designing Smarter Adenoviral Vector Delivery of Vaccines: What Has Translated Successfully into Humans
A.Nicosia
23 June 2010, Roche Partnering GEM Event, Paris, France. Invited speaker
Smarter Adenoviral vectors for HCV prophylactic & therapeutic vaccine
A. Folgori
10-11 June 2010, Use of humanized mice to accelerate vaccine and drug discovery, Workshop, Hannover, Germany. Invited speaker
Humanized mice as tool to study HCV entry inhibitors
P. Meuleman
7-11 May 2010, 97th Annual Meeting of the American Association of Immunologists, , Baltimore, MD, USA
Hepatitis C Virus-specific immune response among needle-stuck Egyptian healthcare workers at high risk of infection without viremia or seroconversion (#804215)
S. Abdelwahab, E. Rewisha, M. Sobhy, I. Galal, Z.A. Zakaria, M. A. Mahmoud, S. Capone, A. Folgori, M. Hashem, S.S. El-Kamary, G.T. Strickland, R. Cortese, A. Nicosia
28 April 2010, Vaccine Innovation, Frankfurt, Germany. Invited speaker
Designing Smarter Adenoviral Vector Delivery of Vaccines: What has Translated Successfully into Humans?
A. Nicosia
30 October – 3 November 2009, AASLD The Liver Meeting 2009, Boston, MA, USA
Phase I trial of a highly immunogenic T cell vaccine for Hepatitis C Virus based on novel, rare, adenoviral vectors
E. Barnes, A. Folgori, S. Aston, K. Smith, M. Ambrosio, V. Ammendola, M. Bartiromo, A. Brown, S. Capone, G. Harrison, I. Humphreys, M. Naddeo, A. Sparacino, L. Siani, C. Traboni, S. Colloca, R. Cortese, A. Nicosia, P. Klenerman
3-7 October 2009, 16th International Symposium on Hepatitis C Virus and Related Viruses, Nice, France
Investigating HCV E1E2 functional domains using linker-scanning mutagenesis
M. Rychlowska, A.M. Owsianka, S.K.H. Foung, K. Bienkowska-Szewczyk , A.H. Patel
3-7 October 2009, 16th International Symposium on Hepatitis C Virus & Related Virus, Nice, France
Phase I trial of a highly immunogenic T cell vaccine for Hepatitis C Virus based on novel, rare, adenoviral vectors (O-44)
A. Folgori, E. Barnes, S. Aston, K. Smith, M. Ambrosio, V. Ammendola, M. Bartiromo, A. Brown, S. Capone, G. Harrison, I. Humphreys, M. Naddeo, A. Sparacino, L. Siani, C. Traboni, S. Colloca, R. Cortese, A. Nicosia, P. Klenerman
3-7 October 2009, 16th International Symposium on Hepatitis C Virus & Related Virus, Nice, France
Optimized function without maximal activation characterizes vaccine-induced CD8 cells that protect upon HCV challenge (O-97)
E.C. Shin, S. Capone, S.H. Park, L. Caggiari, V. De Re, A. Nicosia, A. Folgori, B. Rehermann
POSTERS
28 September – 1 October 2011, SIICA 2011 Annual meeting, Riccione, Italy
Simian adenoviral and MVA vectors combined in a heterologous prime boost strategy - A higly immunogenic novel vaccine against HCV
A. Folgori, E. Barnes, M. Naddeo, S. Capone, J. Meyer, K.E. Smith, R. Huddart, A.C. Brown, A. Kurioka, G.L.A. Harrison, C. Kelly, V. Ammendola, M. Del Sorbo, S. Colloca, L. Siani, C. Traboni, R. Cortese, A. Nicosia, P. Klenerman
28 September – 1 October 2011, SIICA 2011 Annual meeting, Riccione, Italy
Enhancing T cell response and cross-neutralizing antibodies against HCV evenlope by combining adenovisrus and protein
M. Naddeo, A. Chmielewska, V. Ammendola, K. Hu, L. Verhoye, M. Rychlowska, R. Rappuoli, S. Colloca, A. Nicosia, R. Cortese, G. Leroux-Roels, P. Meuleman, K. Bienkowska-Szewczyk, P. Balfe, J.A. McKeatingand, A. Folgori
7-10 November 2010, Gene Based Vaccines, Cannes, France
Phase I trial of a T cell vaccine for Hepatitis C virus based on novel, rare adenoviral vectors
M. Naddeo, A. Folgori, E. Barnes, S. Aston, M. Ambrosio, V. Ammendola, M. Bartiromo, A. Brown, S. Capone, G. Harrison, R. Huddart, J. Meyer, A. Sparacino, L. Siani, K. Smith, C. Willberg, C. Traboni, S. Colloca, R. Cortese, A. Nicosia, P. Klenerman
10-14 September 2010, 17th International Symposium on Hepatitis C and Related Viruses, Yokohama, Japan
Recombinant FLAG-tagged E1E2 from hepatitis C virus elicits the production of cross-reactive antibodies against E2 in mice
V.B. Krapchev, A. Smieszalska, K. Solarz, A. Owsianka, A.H. Patel, K. Bienkowska-Szewczyk
10-14 September 2010, 17th International Meeting on Hepatitis C virus and Related Viruses, Pacifico Yokohama, Japan
Prevalence and incidence of hepatitis C among Egyptian healthcare workers at high risk of infection (P99)
S. Abdelwahab, E. Rewisha, M. Sobhy, I. Galal, N. Mikhail, G. Galal, Z.A. Zakaria, W. Ramadan, T. Abdel-Ghafar, M. El-Tabbakh, M.A. Mahmoud, M. Hashem, S.S. El-Kamary, I. Waked, G.T. Strickland
20-26 March 2010, Keystone Symposia Viral Immunity,Banff, Canada
Phase I trial of a T cell vaccine for Hepatitis C virus based on novel, rare adenoviral vectors
A. Folgori, G. Harrison, E. Barnes, S. Aston, M. Ambrosio, V. Ammendola, M. Bartiromo, A. Brown, S. Capone, R. Huddart, J. Meyer, M. Naddeo, A. Sparacino, L. Siani, K. Smith, C. Willberg, C. Traboni, S. Colloca, R. Cortese, A. Nicosia, P. Klenerman
11-14 November 2009, CSHL meeting Harnessing Immunity to Prevent and Treat Disease, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal anti-HCV antibodies in chimeric mice
P. Meuleman, J. Bukh, A. Farhoudi, I. Desombere, T. Vanwolleghem, H. Alter, R. Purcell, G. Leroux-Roels
3-7 October 2009, 16th International Symposium on Hepatitis C and Related Viruses, Nice, France
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal anti-HCV antibodies in chimeric mice
P. Meuleman, J. Bukh, A. Farhoudi, I. Desombere, T. Vanwolleghem, H. Alter, R. Purcell, G. Leroux-Roels
3-7 October 2009, 16th International Symposium on Hepatitis C Virus & Related Virus, Nice, France
Adenovirus vectors expressing HCV E1E2 glycoproteins induce both neutralising antibodies and t-cell responses in mice (P-176)
A. Smieszalska, M. Naddeo, A. Sparacino, V. Ammendola, M.L. Esposito, S. Capone, M. Rychlowska, Z. Stamataki, J.A. McKeating, K. Bienkowska-Szewczyk, R. Cortese, A. Nicosia, S. Colloca, A. Folgori
22-26 April 2009, EASL - The International Liver Congress 2009, 44th Annual Meeting, Copenhagen, Denmark
Phase I trial of a highly immunogenic T cell vaccine for Hepatitis C Virus based on novel adenoviral vectors from rare serotypes (P2694)
A. Folgori, E. Barnes, S. Aston, K. Smith, A. Brown, M. Ambrosio, V. Ammendola, M. Bartiromo, S. Capone, M. Naddeo, A. Sparacino, L. Siani, C. Traboni, S. Colloca, A.Nicosia, R. Cortese, P. Klenerman
INVITED LECTURES AT UNIVERSITIES, SCHOLARLY INSTITUTIONS AND NATIONAL MEETING
26-27 January 2012, 12ème réunion du réseau national hépatites de l’ANRS. UIC Patrimoine, Paris, France
Novel human antibodies against the hepatitis C virus receptor SR-BI prevent in vivo infection of an escape variant isolated from a liver transplant patient
K. Vercauteren, K. Lacek, K. Grzyb, M. Naddeo, L. Verhoye, M.P. Slowikowski, S. Fafi-Kremer, A.H. Patel, T.F. Baumert, A. Folgori, G. Leroux-Roels, R. Cortese, P. Meuleman, A. Nicosia
14 October 2011, CHU Necker, Paris, France, invited by Dr. Dina Kremsdorf
The chimeric uPA-SCID mouse, a model to evaluate new antiviral therapies
P. Meuleman
27-28 January 2011, 11ème réunion du réseau national hépatites de l’ANRS, UIC Patrimoine, Paris, France, invited by the organizing committee
Prevention of HCV infection by targeting cellular receptors
P. Meuleman
14 December 2010, École Nationale Supérieure de Lyon, Lyon, France, invited by Dr. François-Loïc Cosset
In vivo prevention of HCV entry and spread
P. Meuleman
30 August 2010, CHU Amiens, France, invited by Prof. Dr. Gilles Duverlie
The uPA+/+-SCID mouse: characterization and applications
P. Meuleman
11-17 July 2010, XVI Biotechnology Summer School, University of Gdansk, Sobieszewo/Gdansk, Poland, invited lecturer by Prof. Dr. Krystyna Bienkowska-Szewczyk
The human liver uPA-SCID mouse, a tool to study the human-type metabolism of pharmaceutical compounds
Evaluation of entry inhibitors against the hepatitis C virus
P. Meuleman
24 March 2010, Rockefeller University, New York, NY, USA, invited by Prof. Dr. Charles Rice and Prof. Dr. Alexander Ploss
In vivo prevention and suppression of hepatitis C virus infection by targeting SR-B1
P. Meuleman
28 May 2009, Janssen Pharmaceutica, Johnson and Johnson, Beerse, Belgium,
invited by Dr. Jan Snoeys
The human liver-uPA-SCID mouse: an overview
P. Meuleman
20 February 2009, Insitut de Biologie de Lille – Institut Pasteur de Lille, Lille, France,
invited by Prof. Dr. Jean Dubuisson
The human liver-uPA-SCID mouse: a model for the study of HCV
P. Meuleman
30 September 2008, Rockefeller University, New York, USA, invited by Prof. Dr. Charles Rice
How can a tiny chimeric mouse contribute to the study of HCV?
P. Meuleman
|
